This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Guardian Pharmacy Services, Inc. Class A (GRDN), biote (BTMD) and Argenx Se (ARGX)

Tipranks - Tipranks - Fri May 8, 8:28AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Guardian Pharmacy Services, Inc. Class A (GRDN), biote (BTMD) and Argenx Se (ARGX) with bullish sentiments.

Claim 55% Off TipRanks

Guardian Pharmacy Services, Inc. Class A (GRDN)

In a report released today, David S Macdonald from Truist Financial maintained a Buy rating on Guardian Pharmacy Services, Inc. Class A. The company’s shares closed last Wednesday at $36.58.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 10.2% and a 57.9% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., Ardent Health Partners, Inc., and Aveanna Healthcare Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardian Pharmacy Services, Inc. Class A with a $43.00 average price target, a 14.8% upside from current levels. In a report issued on April 27, Bank of America Securities also initiated coverage with a Buy rating on the stock with a $42.00 price target.

See today’s best-performing stocks on TipRanks >>

biote (BTMD)

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on biote. The company’s shares closed last Wednesday at $2.20.

According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of -13.6% and a 36.7% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Revolution Medicines. ;'>

Currently, the analyst consensus on biote is a Strong Buy with an average price target of $2.50, which is a 12.1% upside from current levels. In a report released today, Roth MKM also reiterated a Buy rating on the stock with a $3.00 price target.

Argenx Se (ARGX)

In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Argenx Se. The company’s shares closed last Wednesday at $807.55.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 14.9% and a 52.4% success rate. Brill covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Centessa Pharmaceuticals, and Maze Therapeutics, Inc. ;'>

Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $1038.75, representing a 29.9% upside. In a report issued on April 23, Citi also maintained a Buy rating on the stock with a $1152.00 price target.

Read More on GRDN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).